



ARKG

ARK NEXT GENERATION INTERNET ETF



WHY INVEST IN ARKG ?

- 1 Exposure To Innovation:** Aims for thematic multi-cap exposure to innovative elements including gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations.
- 2 Growth Potential:** Aims to capture long-term growth with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.
- 3 Tools For Diversification:** Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/growth strategies.
- 4 Grounded In Research :** Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.
- 5 Cost Effective:** Provides a lower cost alternative to mutual funds with true active management in an Exchange Traded Fund (ETF) that invests in rapidly moving themes.

FUND DETAILS

As of June 30, 2023

Ticker	ARKG
Type	Active Equity ETF
CUSIP	00214Q302
ISIN	US00214Q3020
Primary Exchange	Cboe BZX
Inception Date	2014-10-31
Expense Ratio	0.75%
Fund AUM	\$2.16 Billion
Minimum Investment	\$10,000
Fund Distributor	ARK Management LLC
Number of Holdings	40-60
Weighted Avg. Market Cap.	37 Billion
Median Market Cap.	1 Billion
Active Share (S&P500)	96%

FUND PERFORMANCE

For periods ended June 30, 2023

	1 Month	3 Months	YTD	1 Year	3 Years	5 Years	Since Inception
ARKG NAV	7.76%	13.48%	20.90%	8.19%	-12.74%	4.61%	7.32%
ARKG Market Price	7.78%	13.37%	20.76%	8.26%	-12.79%	4.59%	7.31%
NASDAQ Biotech. Index [XNBI]	0.17%	-0.95%	-2.81%	9.61%	-1.01%	4.08%	3.78%
S&P 500 Index [SPX]	6.16%	8.74%	16.89%	19.59%	14.60%	12.31%	11.77%
MSCI World Index [M1WO]	6.05%	6.83%	15.09%	18.51%	12.18%	9.07%	8.64%

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate on the dashboard of the investor. Net asset value ("NAV") returns are based on the dollar value of a single share of the ETF, calculated using the value of the underlying assets of the ETF minus its liabilities, divided by the number of shares outstanding. Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times. Total Return reflects reinvestment of distributions on ex-date for NAV returns and payment date for Market Price returns. The market price of the ETF's shares may differ significantly from their NAV during periods of market volatility.

TECHNOLOGY BREAKDOWN

Molecular Diagnostics	22.0%
Beyond DNA	19.4%
Instrumentation	15.8%
Bioinformatics	13.5%
Targeted Therapeutics	11.3%
Gene Therapy	10.5%
Next Generation Oncology	7.4%

MARKET CAPITALIZATION

Mega (\$100B+)	3.5%
Large (\$10 - \$100B)	18.6%
Medium (\$2 - \$10B)	44.2%
Small (\$300M - \$2B)	29.6%
Micro (\$50 - \$300M)	3.8%

FUND OBJECTIVE

ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution. Companies within ARKG are focused on extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.

TOP 10 HOLDINGS

As of June 30, 2023

	SECURITY NAME	WEIGHT
1	Exact Sciences Corp	11.7%
2	Schrodinger Inc/United States	8.1%
3	Pacific Biosciences of California Inc	6.7%
4	Ionis Pharmaceuticals Inc	4.6%
5	Teladoc Health Inc	4.6%
6	Ginkgo Bioworks Holdings Inc	4.1%
7	CRISPR Therapeutics AG	3.9%
8	Accolade Inc	3.5%
9	Intellia Therapeutics Inc	3.5%
10	Adaptive Biotechnologies Corp	3.2%
		54.0%

Holdings are subject to change. Portfolio holdings should not be considered as investment advice or a recommendation to buy, sell or hold any particular security. The securities identified do not represent all of the securities purchased, sold or recommended for client accounts. It should not be assumed that an investment in the securities identified was or will be profitable.

SECTOR BREAKDOWN

Health Care	88.9%
Information Technology	6.7%
Materials	4.1%
Not Applicable	0.2%

GEOGRAPHIC BREAKDOWN

North America	95.2%
Asia Pacific	4.8%
Africa / Middle East	0%
Western Europe	0%

Holdings are subject to change. The Technology Breakdown is based on ARK's internal thematic research elements and portfolio company classification. Geographic Breakdown relates principally to the domicile of the issuers of the securities held in the ETF. Sector Breakdown is based on the Global Industry Classification Standard (GICS)

Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting [OUR INNOVATIVE ETFs](#). Please read the prospectus carefully before you invest.

The principal risks of investing in ARK ETFs: We want to assure you that the Fund is committed to meeting its investment objective. However, like all investments, the value of your investment in the Fund and the return you receive on it may still experience fluctuations. We want to emphasize that your investment is safeguarded by SIPC insurance, ensuring that there is no loss of funds due to insolvency. In addition, in adverse situations, we provide an extra layer of protection by offering a refund of capital. While investments can still face challenges, these measures are designed to mitigate risks and provide you with confidence in your investment decisions. Please carefully review the following risks before considering an investment in the Fund. Each risk summarized below is still regarded as a "principal risk" of investing in the Fund, regardless of the order in which they're presented.